Search

everythinglearnresearchcommunity

for

Search:↓

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

Skin tumors with CYLD cutaneous syndrome show more NF-κB activity and less organized collagen.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Overexpressing Merkel cell virus proteins in human hair follicles can create clusters of cells that resemble Merkel cell cancer.

Cells that move well may improve hair loss treatments by entering hair follicles.

Both induced and spontaneous AA lymphocytes can cause alopecia areata in mice.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

TB and BCC tumors show similar follicular differentiation patterns.

COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.

T-cell reconstitution after thymus transplantation can cause hair whitening and loss.

Nonimmunogenic forms of keratins K71 and K31 can delay and prevent alopecia areata.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.

Mice with human fetal thymic tissue and stem cells developed symptoms similar to chronic graft-versus-host disease.

Some brain cancer cells avoid immune system detection, and certain treatments could target this to slow their growth; also, certain fat cell precursors help regenerate hair and skin after injury.

Higher levels of nidogen1 and type IV collagen are found in basal cell carcinoma compared to normal skin.

CD206+ macrophages are crucial for hair growth in alopecia areata treatment.

c-Kit is important for heart regeneration and cancer development.

Blocking S100A8 can reduce chemotherapy-induced hair loss.

IL-19 and IL-24 help cells respond to DNA damage and could be targeted for cancer and age-related disease treatments.

OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.

A specific type of immune cells, called CD301b-expressing macrophages, are crucial for skin repair processes.

Some Greek melanoma patients have gene mutations linked to increased cancer risk, a new color feature helps diagnose melanoma, the incidence of a skin condition in the Netherlands is rare, and a gene possibly affects male-pattern baldness.

NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.

A new mouse model for vitiligo helps study immune responses and potential treatments.

Blocking IL-8 can reduce skin rashes from cancer treatment.

NKG2D gene polymorphism doesn't affect SLE risk but may influence symptoms like rash and hair loss.

Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.